ARTICLE OPEN

Integrated omics profiling of dextran sodium sulfate-induced colitic mice supplemented with Wolfberry (*Lycium barbarum*)

Wanping Aw^{1,2,7}, Huijuan Jia^{1,7}✉, Weida Lyu¹, Shinji Fukuda^{2,3,4,5,6}, Masaru Tomita², Lila Otani¹ and Hisanori Kato¹✉

We used a multi-omics profiling approach to investigate the suppressive effects of 2% Wolfberry (WOL)-enriched diets on dextran sodium sulfate (DSS)-induced colitis in mice. It was observed that in mice fed the WOL diet, the disease activity index, colon shortening, plasma concentrations of matrix metalloproteinase-3 and relative mesenteric fat weight were significantly improved as compared to the DSS group. Results from colon transcriptome and proteome profiles showed that WOL supplementation significantly ameliorated the expression of genes and proteins associated with the integrity of the colonic mucosal wall and colonic inflammation. Based on the hepatic transcriptome, proteome and metabolome data, genes involved in fatty acid metabolism, proteins involved in inflammation and metabolites related to glycolysis were downregulated in WOL mice, leading to lowered inflammation and changes in these molecules may have led to improvement in body weight loss. The integrated nutrigenomic approach thus revealed the molecular mechanisms underlying the ameliorative effect of whole WOL fruit consumption on inflammatory bowel disease.

npj Science of Food (2020)4:5; <https://doi.org/10.1038/s41538-020-0065-5>

INTRODUCTION

Inflammatory bowel disease (IBD) is a group of debilitating inflammatory disorders that affect the gastrointestinal tract. IBD includes Crohn's disease (CD) and ulcerative colitis (UC). Affected patients experience various symptoms associated with gut inflammation, ranging from abdominal pain and diarrhea to rectal bleeding and weight loss. Physicians usually recommend using anti-inflammatory steroids or immunosuppressants to reduce inflammation¹. Dietary interventions² using nutraceuticals³, probiotics, prebiotics², lifestyle interventions and recently, fecal microbiota transplantation⁴ are commonly used as alternatives to medical therapy in IBD management^{5–7}.

Wolfberry (WOL), the fruit of *Lycium barbarum* (member of Solanaceae), is a sweet red berry that has been used traditionally as a medicinal food in China and other Asian countries like Vietnam, Japan and Korea^{8,9}. WOL comprises of various polyphenols¹⁰ including phenylpropanoids, coumarins, lignans, flavonoids, iso-flavonoids, chlorogenic acid derivatives¹⁰. It also consists of carotenoids (zeaxanthin and carotene)^{11,12}, polysaccharides^{13,14} and small molecules such as betaine¹⁵, cerebroside¹⁶, β -sitosterol and various vitamins¹⁷. Valuable components of WOL include zeaxanthin, a non-provitamin A carotenoid shown to protect the eyes¹⁸ and to enhance immune response^{19,20}. Studies have suggested that WOL consumption may have neuroprotective^{21,22}, anti-aging²³, prevention of Alzheimer's Disease²², and immune-boosting properties^{9,24,25}. WOL polysaccharides also have been reported to have anti-diabetic properties²⁶, improve retinopathy in diabetic rats²⁷ and improve diabetic testicular dysfunction²⁸. It also has been documented that WOL polysaccharide fractions can protect against renal damage²⁹ and reduce immunotoxicity³⁰. It has been previously reported that a milk-based WOL preparation can suppress 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced

colitis³¹ and WOL can suppress dextran sulfate sodium (DSS)-induced colitis³².

Although there are many reports on WOL constituents, there are in fact very few studies using whole WOL even though it is often consumed whole in cuisine, dessert or infused in hot water. In this study, we used a nutrigenomics-based multidimensional approach is used to determine the effects of whole WOL nutritional-intervention dietary signals on the status of genes, proteins and metabolites. We sought to identify the dietary signature of WOL interactions in murine hosts and to elucidate potential molecular mechanisms in a DSS-induced colitis mouse model via comprehensive transcriptome, proteome, and metabolome evaluations not only using colon and but also liver tissues, which is an important metabolic powerhouse in the host.

RESULTS

General characteristics

No significant differences were observed in food intake before DSS (CON: 27.0 ± 2.3 ; DSS: 27.7 ± 4.7 ; DSSWOL: 24.8 ± 2.3 g) or after DSS administration (CON: 40.6 ± 9.9 ; DSS: 37.1 ± 7.9 ; DSSWOL: 32.3 ± 2.3 g). Water intake during the DSS administration period are as follows: CON: 26.5 ± 0.6 ; DSS: 24.2 ± 1.5 ; DSSWOL: 24.8 ± 1.2 mL. The DSS intakes of the DSS and DSSWOL mice were thus not significantly different. The mice that were DSS-challenged presented with significant pathological changes, including severe body weight loss, presence of fecal occult blood, and diarrhea, resulting in a significant increase in the DAI compared to the CON group (Fig. 1a).

WOL supplementation suppressed these pathological conditions of IBD, resulting in a decrease in the DAI values from day 7 to day 9 (Fig. 1a). Mice from the DSS group had significantly shorter

¹Health Nutrition, Graduate School of Agricultural and Life Sciences, the University of Tokyo, 1-1-1, Yayoi, Bunkyo-Ku, Tokyo 113-8657, Japan. ²Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata 997-0052, Japan. ³Intestinal Microbiota Project, Kanagawa Institute of Industrial Science and Technology, 3-25-13 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan. ⁴Transborder Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8577, Japan. ⁵PRESTO, Japan Science and Technology Agency, 4-1-8 Honcho Kawaguchi, Saitama 332-0012, Japan. ⁶Metabologenomics, Inc., 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata 997-0052, Japan. ⁷These authors contributed equally: Wanping Aw, Huijuan Jia. ✉email: ginajh77@yahoo.co.jp; akatoq@mail.ecc.u-tokyo.ac.jp

Fig. 1 General characteristics. **a** The disease activity index (DAI) was calculated by combining the scores of body weight loss, stool consistency, and fecal blood, and then dividing the score by 3. Each score was determined as follows: change in body weight (0: <1%; 1: 1–5%; 2: 5–10%; 3: 10–15%; 4: >15%), fecal blood (0: no fecal blood observed; 2: ++; 4: ++++) and stool consistency (0: normal; 2: soft; 4: diarrhea). **b** Length of colon. **c** Relative mesenteric fat. **d** Plasma Mmp3 levels. **e** Plasma Il6 concentrations. **f** H&E staining of the colon. All values are the means $\pm$ SD ($n = 6–7$). Data with different letters (a, b, c) are significantly different at $p < 0.05$ by Dunnett's test. p value in the bracket is vs. DSS.

colon lengths (Fig. 1b) and lower mesenteric fat weight (Fig. 1c) compared to the control group, and WOL significantly ameliorated these decreases. The plasma Mmp3 (Fig. 1d) levels were significantly increased by DSS administration, and the WOL intervention significantly mitigated these increases. The concentrations of Il6 in the plasma (Fig. 1e) tended to be improved by WOL supplementation.

Colonic microarray analysis

Messenger RNAs for 2189 genes were differentially expressed in the DSS mice compared to the controls. Among these genes, 271 genes were upregulated in DSSWOL and 207 genes were downregulated compared to the DSS (Supplementary Table 1). WOL decreased the gene expression levels of tissue inhibitor of metalloproteinase 1 (*Timp1*) and chemokines belonging to the chemokine (C–C motif) ligand (Ccl): *Ccl1* and *Ccl5*. In addition, a lower expression level of proinflammatory cytokine of interleukin 1 receptor type 1 (*Il1r1*) was observed. Other downregulated genes included secreted phosphoprotein 1 (*Spp1*), haptoglobin (*Hp*) and prostaglandin-endoperoxide synthase 2 (*Ptgs2*). Some of the downregulated genes were related to the breakdown of extracellular matrix and remodeling matrix metalloproteinase (MMP), i.e., *Mmp3*, *Mmp13* and *Mmp10*; cluster of differentiation (*Cd163*) and *Il6*, were selected for validation by real-time RT-PCR. DSS significantly upregulated the expressions of *Mmp10*, *Hp*, *Il6*, *Mmp3*, and *Timp1*. WOL supplementation significantly attenuated these increases in *Hp*, *Timp1*, and *Mmp10* and tended to improve these upregulations in *Il6*, *Cd163*, and *Mmp3* (Fig. 2).

Hepatic microarray analysis

In the liver, 12,838 genes were differentially expressed in DSS compared to the controls. In the DSSWOL group, 1630 genes were upregulated and 1793 genes were downregulated compared to the DSS mice (Supplementary Table 2). WOL supplementation decreased the expression of genes for molecules of cancer

markers such as serum amyloid A1 (*Saa1*), c-Jun (*Jun*), and S100 calcium-binding protein A8 (*S100a8*). In addition, genes involved in the fatty acid synthesis, i.e., stearoyl-CoA desaturase-1 (*Scd1*), ELOVL family member 6, elongation of long chain fatty acids (*Elovl6*), fatty acid synthase (*Fas*), and NADP-dependent malic enzyme (*Me1*) were upregulated. The gene expression level of methionine adenosyltransferase II, alpha (*Mat2a*), which is involved in the methionine-recycling pathway, was decreased. Based on the results of the validation of gene expression by real-time RT-PCR (Fig. 3), DSS significantly regulated the expression of *Elovl6*, *Fas*, *Jun*, *Mat2*, *Me1*, *Saa1*, *Scd1*, and *S100A8*, and WOL supplementation significantly affected the expression of these genes—except for *Jun* and *Saa1*, on which WOL tended to have a suppressive effect.

Comparative hepatic and colonic proteomics analysis by iTRAQ

We determined the global protein expression in the three groups by using iTRAQ labeling quantitative proteomic technology. We included a 1.2- or 0.8-fold cut-off from unique proteins quantified at the >95% confidence level when classifying proteins as highly up- or downregulated.

In the liver, we identified 222 proteins, of which 58 proteins were downregulated and 75 proteins were upregulated in DSSWOL compared to the DSS group (Supplementary Table 3). WOL supplementation decreased the levels of proteins that are known to be commonly upregulated in IBD patients: calreticulin (*Calr*)³³, serotransferrin (*Trfe*)³⁴, annexin A5 (*Anxa5*)³⁵, beta-enolase (*Enob*)³⁶, transthyretin (*Tthy*)³⁷, selenium-binding protein 1 (*Sbp1*)³⁸, and protein-glutamine gamma-glutamyltransferase 2 (*Tgm2*)³⁹; proteins involved in fibrosis: fibrinogen beta chain (*Fibb*) and fibrinogen gamma chain (*Fibg*)⁴⁰; and inflammation-related proteins: histone H4 (*H4*), superoxide dismutase [Cu–Zn] (*Sodc*)⁴¹, cystatin-B (*Cytb*)⁴², 10-kDa heat shock protein, mitochondrial (*Ch10*)⁴³, thioredoxin (*Thio*)⁴⁴, and alpha-enolase (*Enoa*)⁴⁵.

In the colon, we detected a total of 2,111 proteins, of which 271 were upregulated and 217 were downregulated in the DSSWOL

Fig. 2 Colonic mRNA relative expressions of genes related to the breakdown of extracellular matrix and tissue remodeling, inflammation and IBD. Mmp3, Mmp10, Mmp13, Timp1, Hp, Il6, and Cd163 were measured by RT-PCR and normalized to Rplp1. All values are the means $\pm$ SD ($n = 6-7$). Data with different letters (a, b, c) are significantly different at $p < 0.05$ by Dunnett's test. p value in the bracket is vs. DSS.

group compared to the DSS group (Supplementary Table 4). WOL supplementation increased the levels of several proteins, including trefoil factor 3 (Tff3), a protein involved in intestinal tight junction integrity and mucus protection⁴⁶; anterior gradient protein 2 homolog (Agr2)⁴⁷; the anti-inflammation-related protein carboxypeptidase E (Cbpe)⁴⁸; and a protein related to DNA repair, 40S ribosomal protein S3 (Rs3)^{49,50}.

Compared to the DSS group, the downregulated proteins in the DSSWOL group were: a negative modulator of leukocyte inflammatory responses, tyrosine-protein phosphatase non-receptor type substrate 1 (Shps1)⁵¹; a marker protein in IBD patients, isoform S-gicerin of cell surface glycoprotein MUC18 (Muc18)⁵²; an IBD risk factor protein, apolipoprotein E (ApoE)⁵³; neural cell adhesion molecule L1 (L1cam)⁵⁴; a protein related to inflammation and tissue injury resistance, ceruloplasmin (CerU)⁵⁵; two proteins involved in tumor progression, annexin a3 (Anxa3)^{56,57} and complement C3 (Co3)⁵⁸; and neutrophil gelatinase-associated lipocalin (Ngal)⁵⁹.

Plasma and hepatic metabolome evaluation

To evaluate metabolic alteration by WOL consumption, we performed liver and plasma metabolome analyses of the CON, DSS, and DSSWOL groups based on their m/z values and migration times. The numbers of metabolites detected in the liver tissue and plasma were 131 and 117, respectively. Normalized metabolomics data was used for hierarchical clustering for a heatmap representation and further analyzed by a principal component analysis (PCA) using MeV software.

Although no obvious variations among the groups were observed in the heatmap (Fig. 4a, b), distinct clusters were formed among the CON, DSS, and DSSWOL groups (Fig. 4c, d). Ten

metabolites in liver (Supplementary Table 5a) and four metabolites (Supplementary Table 5b) in plasma were significantly regulated by DSS administration and subsequently improved by WOL supplementation. These metabolites included hepatic metabolites involved in the pentose phosphate pathway, i.e., glucose-6-phosphate dehydrogenase (G6P) and fructose 6-phosphate (F6P); and in purine metabolism, i.e., adenosine monophosphate (AMP), inosine monophosphate (IMP) and guanosine monophosphate (GMP). The other metabolites were two molecules related to the methionine-recycling pathway, glutathione and S-lactoylglutathione, and a product of collagen degradation, i.e., hydroxyproline. The upregulation of 2-hydroxyisobutyrate, dodecanoate, and arginine was observed in plasma metabolome profiles.

DISCUSSION

We comprehensively examined the impact of WOL supplementation on the inflamed colon and liver transcriptome and proteome, as well as the plasma and liver metabolome profiles. Our results revealed that WOL dietary supplementation may ameliorate DSS-induced colonic injury and inflammation and enhance gut barrier defense by maintaining mucosal integrity, as described below. Our findings also revealed modulated metabolic pathways and potential key gene/protein regulatory hubs that may regulate these processes. Our experimental approach of WOL feeding prior to DSS challenge can be regarded as similar to the patterns of the consumption of various food products by IBD patients during a period of fluctuating disease activity⁶⁰. To our knowledge, this is an unprecedented report of the use of pure

Fig. 3 Hepatic mRNA expressions of genes related to fatty acid synthesis and to cancer markers, and genes involved in glycolysis. The relative mRNA expressions of *Elovl6*, *Fas*, *Me1*, *Scd1*, *Jun*, *Saa1*, *Mat2a*, and *S100A8* were measured by RT-PCR and normalized to *Ppia*. All values are the means $\pm$ SD ($n = 6-7$). Data with different letters (a, b, c) are significantly different at $p < 0.05$ by Dunnett's test. p value in the bracket is vs. DSS.

whole WOL in IBD using a comprehensive nutrigenomics approach, particularly in UC.

Our colon gene expression data revealed that WOL intervention suppresses colonic inflammation. Inflammatory responses in IBD usually begin with an infiltration of neutrophils and macrophages⁶¹, and thereafter a mixture of inflammatory cytokines, including *IL6*, *IL1* and *TNF*⁶², is secreted. This results in the production of proteases, free radicals, and metalloproteinases which are responsible for colon shortening, tissue degradation, and lesion development⁶³. In the present study, the global colon gene expression and RT-PCR validation revealed a tendency of downregulation of *Il6*, and its downstream factors, *Mmp10* and *Hp*, were reduced significantly by WOL intervention. The expression of *Hp* has been associated with inflammation is also significantly reduced in inflammatory conditions⁶⁴. The downregulation of proteins related to inflammation and tissue injury (Ceru and Shps1) and the genes *Hp*, *Mmp10*, *Timp1* in our DSSWOL group suggests that the WOL intervention lowered the extent of inflammation in the colon induced by DSS.

WOL intake preserved the integrity of the mucosal barrier which is an important component of a healthy gut, as it represents the first line of defense between the luminal content and host tissues. A damaged mucosal barrier enables microbial interactions with the colonic mucosa, which can stimulate host innate and inflammatory immune responses. Downregulation of fibrosis-related proteins, i.e., *Fibb* and *Fibg*⁶⁵, and genes of metalloproteinases were observed in DSSWOL mice as compared to DSS. The significantly downregulated expression level of *Mmp10* and plasma *Mmp3* by WOL intervention could help prevent the

degradation of a broad range of extracellular components including proteoglycans, type II, type IV, type IX and type XI collagens, laminin, and fibronectin⁶³, thereby inhibiting the degradation of the mucosal wall that is manifested in IBD patients⁶⁶.

WOL supplementation also improved mucosal barrier integrity via modulating the expression levels of the protein Tff3, which is commonly expressed in the gastrointestinal tract and in most of the mucosal membranes^{67,68}, is able to maintain the integrity of the tight junctions and maintain intestinal barrier function by protecting the epithelial layer in combination with mucin⁶⁹. This protein is also related to angiogenesis and anti-apoptosis by its combined action with mucins⁶⁷. Intestinal goblet cells secrete not only the MUC2 mucin but also a number of typical mucus components including AGR2, and TFF3⁷⁰. The upregulation of Tff3 in the present DSSWOL group indicates that WOL supplementation improved the integrity of the intestinal barrier function and tight junction that had been degraded by DSS administration. The protein Agr2 secreted by epithelial cells plays a vital function in the synthesis of the intestinal mucin Muc2, which is a type of cysteine-rich glycoprotein that develops the mucus gel lining the intestine. Agr2 deficiency is suggested to lead to susceptibility to IBD⁷¹. Prior in vivo research also revealed that Agr2 is related to the maintenance of epithelial integrity in a mouse model⁴⁷. In our present investigation, WOL intervention enhanced not only the expression of Agr2 but also the colonic mucosal defense function in DSS-challenged mice.

Despite a relatively short DSS administration period, WOL intervention improved the expression levels of cancer-related

Fig. 4 The normalized tabolomics data were hierarchically clustered on both the metabolite and sample axes for a heatmap representation and further analyzed by PCA using MeV and XLSTAT software. No distinct difference among the three groups was observed in the heatmap (a, b) but distinct clusters were formed among CON, DSS, and DSSWOL in the PCA data analysis (c, d) of both plasma and liver metabolites.

proteins in the colon (Anxa3 and Co3) as well as oncogenic hepatic genes (*Saa1*, *Jun* and *S100a8*) as observed in the DSSWOL mice as compared to the DSS group. It has been reported that 2% of IBD cases progress to colorectal cancer (CRC) and account for 15% of CRC-related deaths. Axelrad et al. and Pedersen et al. also reported that in IBD patients, long-term exposure to chronic inflammation is the primary risk factor for CRC development as well as other types of cancers^{72,73}. By lowering the expression of these cancer-related markers and proteins commonly expressed in IBD patients (Muc18, Apoe, L1cam), WOL intervention might delay the onset of IBD-related CRC.

WOL intake also improved the metabolic pathways involved in glycolysis. During inflammation, numerous immune cells are activated and migrate to inflammatory lesions. Phagocytosis, bacteria-killing and stimulated cell proliferation have high energy demands⁷⁴. Neutrophils, macrophages, and dendritic cells primarily use glycolytic pathways to obtain energy, whereas B and T cells mainly use amino acids, glucose, and lipids to generate energy during oxidative phosphorylation. Nutrition and oxygen are rapidly limited or depleted in tissues with high inflammatory lesions and elicited immune activities⁷⁵. Hepatic metabolites involved in glycolysis, i.e., G6P and F6P have been significantly upregulated by WOL supplementation, indicating that WOL plays an active role in glycolytic recovery. A significant upregulation of genes involved in fatty acid metabolism (*Fas*, *Me1*, *Scd1*, and *Elovl6*) by WOL supplementation as well as the metabolic shifts in

glycolysis could have contributed to the improved body weight loss in the DSSWOL mice induced by DSS administration. This observation was in accord with the lowered expressions of inflammatory proteins in the liver, such as H4, Sodc, and Cytb.

Our data also showed that WOL intervention could prevent the onset of any early event prior to IBD. In most cases, an inhibitory effect of DSS treatment on *SCD1* in the liver has been characterized as an early event prior to IBD clinical symptoms⁷⁶. The disruption of intestinal microflora and the release of endotoxins following DSS treatment may contribute to the acceleration of DSS-induced colitis⁷⁶. Direct downstream targets of endotoxins and bacterial infection include proinflammatory cytokines, such as interleukins and *TNFA*, which can subdue *SCD1* expression. Since we observed that the *Il6* expression levels were dramatically upregulated by DSS treatment, it is likely that a portal vein delivery of inflammatory markers from the colon contributes to the suppression of *Scd1* expression in the liver. In IBD patients, hepatobiliary manifestations are frequently observed as the gastrointestinal tract and the hepatobiliary system is anatomically close, and due to the mesenteric venous drainage ascending via the portal vein into the liver⁷⁷. WOL treatment downregulated the colonic expression of *Il6*, leading to a decrease in cytokines delivered to the liver, thereby resulting in the upregulation of *Scd1* and preventing the onset of an early event prior to IBD clinical symptoms.

Fig. 5 Schematic summary of the integrated omics profiling of WOL intervention in the DSS-colitic mouse model.

As demonstrated above, we employed a nutrigenomics approach to obtain evidence-based insights into the effect of whole WOL supplementation on IBD (Fig. 5). The integrated colon transcriptome and proteome profiles also indicated that 2% WOL supplementation in DSS-challenged mice significantly ameliorated inflammation in the colon, which maintained the integrity of the colonic mucosal wall and might have prevented the risk factors leading to the pathogenesis to CRC. The hepatic transcriptome, proteome, and metabolome data showed that in WOL-fed mice, genes involved in fatty acid metabolism, proteins involved in inflammation, and metabolites related to glycolysis were ameliorated, leading to lowered inflammation and could have contributed to the improvements in body weight. Taken together, our findings provide integrated nutrigenomics information regarding the effect of WOL, a traditional Chinese fruit, on a colitic model. Our results can be expected to be impactful, as the daily inclusion of WOL in a diet could be a dietary strategy to maintain gut health and reduce disease severity in mucosal damage-associated pathologies.

METHODS

Animals and dietary treatment

Animal care and treatment were approved based on the institutional ethical guidelines at the University of Tokyo and approved by the animal experiment committee of the Faculty of Agriculture, The University of Tokyo (Approval no. P13–739). Seven-week-old male C57BL/6J mice (Charles River Japan, Tokyo) were housed individually in animal cages in a room with controlled temperature ($23 \pm 2^\circ\text{C}$), humidity ($50 \pm 10\%$), and a 12-h light (08:00–20:00) and dark (20:00–08:00) cycle throughout the experimental period. After 3 days' acclimatization, the mice were divided into three groups of 6–7 mice each with equivalent body weights, and provided with the following diets (Supplementary Table 6a) and drinking water: (1) AIN-93G basal diet and tap water for the course of the entire experiment (controls; CON), (2) AIN-93G basal diet and tap water for 1 week, after which colitis was induced by administering tap water containing 1.5% (w/v) DSS (molecular weight, 40 kDa; MP Biomedicals, Irvine, CA) (the DSS group), and (3) 2% WOL-supplemented AIN-93G basal diet throughout the experimental period, along with colitis induced after 1 week in the same manner as for the DSS group (DSSWOL). The pre-DSS period lasted for 7 days and DSS-drinking water was administered during the last 9 days of the experimental period. WOL powder (Natural Life, Inc., Tokyo) was made from grinding dried WOL. The nutritional content in 100 g dried WOL are as follows: 9.7 g protein, 0.4 g fat, 77.1 g carbohydrate, 45.6 g sugar, 13 g dietary fiber, 7.5 g moisture, and 0.8 g ash. The food

intake, water intake, and DSS intake of each group were monitored carefully throughout the experiment.

Evaluation of disease activity index (DAI)

During the DSS challenge, the body weight, stool consistency, and fecal blood were recorded daily as criteria for the DAI⁷⁸. The DAI was calculated by combining these three scores and then dividing the score by 3. Each score was determined as follows: change in body weight (0: <1%; 1: 1–5%; 2: 5–10%; 3: 10–15%; 4: >15%), fecal blood (0: no fecal blood observed, 2: bleeding mixed with normal feces observed, 4: only blood observed) and stool consistency (0: normal, 2: soft, 4: diarrhea).

Blood collection and tissue harvesting

Mice were sacrificed at the end of the experimental period with sodium pentobarbital followed by bleeding from the carotid artery, and plasma samples were stored at -80°C after centrifugation ($1000 \times g$, 15 min, 4°C). The colon length (from the ileocecal junction to the proximal rectum) of each mouse was measured and used as a parameter for colitis severity. Excised colon and liver samples as well as mesenteric adipose tissues were snap-frozen in liquid nitrogen and stored at -80°C until further analysis.

Biochemical tests

Plasma concentrations of interleukin-(IL)6 and matrix metalloproteinase-3 (MMP3) were measured using enzyme-linked immunosorbent assay (ELISA) kits (Thermo Scientific, Rockford, IL and R&D Systems, Minneapolis, MN, respectively), according to the manufacturer's instructions.

Total RNA extraction and transcriptome analysis

Total RNA was extracted from the frozen liver and colon samples. Its concentration was determined from the optical density at 260 nm on a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA), and the purity was assessed by determining the A260/A280 ratio⁷⁹. RNA from each respective group was pooled ($n = 6-7$), and colonic and hepatic transcriptome evaluations were carried out. We used Affymetrix GeneChip Command Console® software to analyze the gene expression ratios of the DSS versus CON group data and the DSSWOL versus DSS group data. Array images were analyzed with Microarray Suite ver. 5.0 (MAS5) (Affymetrix). Genes whose expressions changed more than 1.2-fold between treatments were considered to be differentially expressed.

Real-time reverse transcription polymerase chain reaction (RT-PCR)

To detect and validate the expression of differentially expressed genes related to inflammation and IBD, we carried out an RT-PCR using the real-

time PCR detection system (Takara Bio, Madison, WI, USA)⁷⁹. Final mixture (12.5 µL) for RT-PCR consisted of 1 × SYBR Premix Ex Taq Mix (Takara), 0.4 µM of each forward and reverse primers and 1 µL of cDNA. Primers were designed using PRIMER3, and their sequences are as detailed in Supplementary Table 6b. Relative mRNA expressions were normalized to 60S acidic ribosomal protein P1 (*Rplp1*) in the colon and peptidyl-prolyl cis-trans isomerase (*Ppia*) in the liver. Gene expression data are presented as the fold change of normalized mRNA amounts of each sample compared to those from the DSS group.

Protein preparation, itraq labeling, and nanolc-ms/ms analysis for proteome analysis

Total hepatic and colonic protein were extracted and prepared according to manufacturer's instructions (AB SCIEX, Framingham, MA). The preparation was then iTRAQ labeled and subjected to nanoscale liquid chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS) analysis. We conducted the protein identification and quantification for iTRAQ samples using ProteinPilot software (ver. 4.0, AB SCIEX) with 95% confidence against switchProt. We used the Paragon Algorithm in the ProteinPilot software for the peptide identification and isoform specific quantification⁷⁸.

Metabolome analysis

The metabolome profiles were evaluated by extracting metabolites from frozen plasma and liver samples by adding 400 µL of methanol including the internal standards (20 µM each of methionine sulfone and D-camphor-10-sulfonic acid (CSA)) was added to the 40 µL of samples. Next, this mixture was then mixed with 120 µL of ultrapure water and 400 µL of chloroform before centrifuging at 10,000 × *g* for 3 min at 4 °C. Thereafter, proteins and lipids were removed by transferring the aqueous layer to a centrifugal filter tube (UltrafreeMC-PLHCC 250/pk for Metabolome Analysis, Human Metabolome Technologies). The filtrate was centrifugally concentrated and dissolved in 20 µL of ultrapure water that contained reference compounds (200 µM each of 3-aminopyrrolidine and trimelic acid) immediately before CE-TOFMS analysis⁸⁰. All CE-TOFMS experiments were performed using the Agilent CE capillary electrophoresis system (Agilent Technologies). Annotation tables were produced from the measurement of standard compounds that were aligned with the datasets according to similar value and normalized migration time. Peak areas were then normalized against those of the internal standards methionine sulfone or CSA for cationic and anionic metabolites, respectively. The concentrations of each metabolite were calculated based on their relative peak areas and concentrations of standard compounds.

Statistical analysis

All data relating to general characteristics, biochemical parameters, relative gene expression, and relative metabolite concentrations are presented as the mean ± standard deviation (SD). We analyzed the data by performing a one-way analysis of variance (ANOVA) and Dunnett's test (BellCurve for Excel, Social Survey Research Information Co., Ltd). Differences were considered statistically significant at *p* < 0.05 compared to the DSS group.

DATA AVAILABILITY

The authors declare that [the/all other] data supporting the findings of this study are available within the paper (and its supplementary information files). The data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 30 May 2019; Accepted: 14 February 2020;
Published online: 31 March 2020

REFERENCES

1. Amezcua, A. J. & Van Assche, G. Practical approaches to "top-down" therapies for Crohn's disease. *Curr. Gastroenterol. Rep.* **18**, 35, (2016).
2. Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. *Nat. Rev. Gastroenterol. Hepatol.* <https://doi.org/10.1038/s41575-019-0173-3> (2019).

3. Uranga, J. A., Lopez-Miranda, V., Lombo, F. & Abalo, R. Food, nutrients and nutraceuticals affecting the course of inflammatory bowel disease. *Pharmacol. Rep.* **68**, 816–826 (2016).
4. Pigneur, B. & Sokol, H. Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. *Mucosal Immunol.* **9**, 1360–1365, (2016).
5. Donnellan, C. F., Yann, L. H. & Lal, S. Nutritional management of Crohn's disease. *Ther. Adv. Gastroenterol.* **6**, 231–242 (2013).
6. Richards, J. L., Yap, Y. A., McLeod, K. H., Mackay, C. R. & Marino, E. Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. *Clin. Transl. Immunol.* **5**, e82 (2016).
7. Triantafyllidis, J. K., Triantafyllidis, A., Vagianos, C. & Papalois, A. Favorable results from the use of herbal and plant products in inflammatory bowel disease: evidence from experimental animal studies. *Ann. Gastroenterol.* **29**, 268–281 (2016).
8. Gao, Y., Wei, Y., Wang, Y., Gao, F. & Chen, Z. Lycium Barbarum: a traditional Chinese herb and a promising anti-aging agent. *Ageing Dis.* **8**, 778–791 (2017).
9. Potterat, O. Goji (Lycium barbarum and L. chinense): phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity. *Planta Med.* **76**, 7–19 (2010).
10. Zhou, Z.-Q. et al. Polyphenols from wolfberry and their bioactivities. *Food Chem.* **214**, 644–654 (2017).
11. Inbaraj, B. S. et al. Determination of carotenoids and their esters in fruits of Lycium barbarum Linnaeus by HPLC–DAD–APCI–MS. *J. Pharm. Biomed. Anal.* **47**, 812–818 (2008).
12. Peng, Y. et al. Quantification of zeaxanthin dipalmitate and total carotenoids in lycium fruits (Fructus Lycii). *Plant Foods Hum. Nutr.* **60**, 161–164 (2005).
13. Xie, J. et al. Effects of polysaccharides in Lycium Barbarum berries from different regions of China on macrophages function and their correlation to the glycosidic linkages. *J. Food Sci.* **82**, 2411–2420 (2017).
14. Cheng, J. et al. An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. *Drug Des., Dev. Ther.* **9**, 33–78 (2015).
15. Shin, Y. G., Cho, K. H., Kim, J. M., Park, M. K. & Park, J. H. Determination of betaine in Lycium chinense fruits by liquid chromatography–electrospray ionization mass spectrometry. *J. Chromatogr. A* **857**, 331–335 (1999).
16. Kim, S. Y. et al. A novel cerebroside from lycii fructus preserves the hepatic glutathione redox system in primary cultures of rat hepatocytes. *Biol. Pharm. Bull.* **22**, 873–875 (1999).
17. Toyoda-Ono, Y. et al. 2-O-(β-D-Glucopyranosyl)ascorbic acid, a novel ascorbic acid analogue isolated from lycium fruit. *J. Agric. Food Chem.* **52**, 2092–2096 (2004).
18. Yu, M., Yan, W. & Beight, C. Lutein and zeaxanthin isomers protect against light-induced retinopathy via decreasing oxidative and endoplasmic reticulum stress in BALB/C mice. *Nutrients* **10**, <https://doi.org/10.3390/nu10070842> (2018).
19. Li, S. Y. et al. Lycium barbarum polysaccharides reduce neuronal damage, blood-retinal barrier disruption and oxidative stress in retinal ischemia/reperfusion injury. *PLoS ONE* **6**, e16380 (2011).
20. Zhou, J. et al. Effects of lycium barbarum polysaccharides on apoptosis, cellular adhesion, and oxidative damage in bone marrow mononuclear cells of mice exposed to ionizing radiation injury. *Biomed. Res. Int.* **2016**, 4147879 (2016).
21. Ho, Y.-S. et al. Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on β-amyloid peptide neurotoxicity. *Brain Res.* **1158**, 123–134 (2007).
22. Yu, M.-S. et al. Neuroprotective effects of anti-aging oriental medicine Lycium barbarum against β-amyloid peptide neurotoxicity. *Exp. Gerontol.* **40**, 716–727 (2005).
23. Chang, R. C.-C. & So, K.-F. Use of anti-aging herbal medicine, lycium barbarum, against aging-associated diseases. What do we know so far? *Cell. Mol. Neurobiol.* **28**, 643–652 (2008).
24. Zhang, Q. et al. Composition of Lycium barbarum polysaccharides and their apoptosis-inducing effect on human hepatoma SMMC-7721 cells. *Food Nutr. Res.* **59**, 28696 (2015).
25. Gan, L., Zhang, S. H., Liu, Q. & Xu, H. B. A polysaccharide-protein complex from Lycium barbarum upregulates cytokine expression in human peripheral blood mononuclear cells. *Eur. J. Pharm.* **471**, 217–222 (2003).
26. Xia, H. et al. An untargeted metabolomics approach reveals further insights of Lycium barbarum polysaccharides in high fat diet and streptozotocin-induced diabetic rats. *Food Res. Int.* **116**, 20–29 (2019).
27. Yao, Q. et al. Lycium barbarum polysaccharides improve retinopathy in diabetic sprague-dawley rats. *Evid.-Based Complementary Alternative Med.* **2018**, 7943212 (2018).
28. Shi, G. J. et al. Lycium barbarum polysaccharide attenuates diabetic testicular dysfunction via inhibition of the PI3K/Akt pathway-mediated abnormal autophagy in male mice. *Cell Tissue Res.* **374**, 653–666 (2018).
29. Li, J. et al. Protective effects of fraction 4a of polysaccharides isolated from Lycium barbarum against KBrO₃-induced renal damage in rats. *Food Funct.* **8**, 2566–2572 (2017).

30. Deng, X. et al. Fraction from lycium barbarum polysaccharides reduces immunotoxicity and enhances antitumor activity of doxorubicin in mice. *Integr. Cancer Therapies* **17**, 860–866 (2018).
31. Philippe, D. et al. Anti-inflammatory effects of Lacto-Wolfberry in a mouse model of experimental colitis. *World J. Gastroenterol.* **18**, 5351–5359 (2012).
32. Kang, Y., Xue, Y., Du, M. & Zhu, M. J. Preventive effects of Goji berry on dextran-sulfate-sodium-induced colitis in mice. *J. Nutr. Biochem.* **40**, 70–76 (2017).
33. Watanabe, K. et al. Anti-calreticulin antibodies in patients with inflammatory bowel disease. *Fukushima J. Med. Sci.* **52**, 1–11 (2006).
34. Bennike, T., Birkelund, S., Stensballe, A. & Andersen, V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. *World J. Gastroenterol.* **20**, 3231–3244 (2014).
35. Fayad, R., Brand, M. I., Stone, D., Keshavarzian, A. & Qiao, L. Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells. *Eur. J. Immunol.* **36**, 2215–2222 (2006).
36. Kwon, S. C. et al. Proteomic analysis of colonic mucosal tissue from tuberculous and ulcerative colitis patients. *Korean J. Physiol. Pharmacol.* **16**, 193–198 (2012).
37. Hansen, J. J., Holt, L. & Sartor, R. B. Gene expression patterns in experimental colitis in IL-10-deficient mice. *Inflamm. bowel Dis.* **15**, 890–899 (2009).
38. Speckmann, B. & Steinbrenner, H. Selenium and selenoproteins in inflammatory bowel diseases and experimental colitis. *Inflamm. bowel Dis.* **20**, 1110–1119 (2014).
39. Rodriguez-Pineiro, A. M. & Johansson, M. E. The colonic mucus protection depends on the microbiota. *Gut microbes* **6**, 326–330 (2015).
40. Boonla, C. et al. Inflammatory and fibrotic proteins proteomically identified as key protein constituents in urine and stone matrix of patients with kidney calculi. *Clin. Chim. Acta* **429**, 81–89 (2014).
41. Tsaprouni, L. G., Ito, K., Powell, J. J., Adcock, I. M. & Punchard, N. Differential patterns of histone acetylation in inflammatory bowel diseases. *J. Inflamm.* **8**, 1 (2011).
42. Jang, S. W. et al. Parasitic helminth cystatin inhibits DSS-induced intestinal inflammation via IL-10(+)F4/80(+) macrophage recruitment. *Korean J. Parasitol.* **49**, 245–254 (2011).
43. Hauet-Broere, F. et al. Heat shock proteins induce T cell regulation of chronic inflammation. *Ann. Rheum. Dis.* **65**(Suppl 3), iii65–68 (2006).
44. El Hadri, K. et al. Thioresdoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. *Arteriosclerosis, Thrombosis, Vasc. Biol.* **32**, 1445–1452 (2012).
45. Vermeulen, N. et al. Anti-alpha-enolase antibodies in patients with inflammatory Bowel disease. *Clin. Chem.* **54**, 534–541 (2008).
46. Xu, L. F., Teng, X., Guo, J. & Sun, M. Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. *Inflammation* **35**, 308–315 (2012).
47. Zheng, W. et al. Evaluation of AGR2 and AGR3 as candidate genes for inflammatory bowel disease. *Genes Immun.* **7**, 11–18 (2006).
48. Bar, F. et al. Carboxypeptidase E modulates intestinal immune homeostasis and protects against experimental colitis in mice. *PLoS ONE* **9**, e102347 (2014).
49. Yadavilli, S. et al. Ribosomal protein S3: a multi-functional protein that interacts with both p53 and MDM2 through its KH domain. *DNA repair* **8**, 1215–1224 (2009).
50. Wang, W. et al. Ribosomal proteins and human diseases: pathogenesis, molecular mechanisms, and therapeutic implications. *Med. Res. Rev.* **35**, 225–285 (2015).
51. Zen, K. et al. Inflammation-induced proteolytic processing of the SIRPalpha cytoplasmic ITIM in neutrophils propagates a proinflammatory state. *Nat. Commun.* **4**, 2436 (2013).
52. Hume, G. E. et al. Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease. *J. Gastrointest. Liver Dis.* **25**, 39–48 (2016).
53. Al-Meghaseeb, E. S. et al. Genetic association of apolipoprotein E polymorphisms with inflammatory bowel disease. *World J. Gastroenterol.* **21**, 897–904 (2015).
54. Sebens, S. & Schafer, H. How two sites of inflammation promote carcinogenesis: The role of macrophages in inflammation associated carcinogenesis. *Oncotarget* **1**, 951–953 (2012).
55. Bakhtadina, B. et al. Protective role of macrophage-derived ceruloplasmin in inflammatory bowel disease. *Gut* **62**, 209–219 (2013).
56. Pan, Q. Z. et al. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. *Mol. Carcinogenesis* **54**, 598–607 (2015).
57. Mussunoor, S. & Murray, G. I. The role of annexins in tumour development and progression. *J. Pathol.* **216**, 131–140 (2008).
58. Ning, C. et al. Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1beta/IL-17A axis. *Mucosal Immunol.* **8**, 1275–1284 (2015).
59. Moschen, A. R. et al. Lipocalin 2 protects from inflammation and tumorigenesis associated with gut microbiota alterations. *Cell Host Microbe* **19**, 455–469 (2016).
60. Zallot, C. et al. Dietary beliefs and behavior among inflammatory bowel disease patients. *Inflamm. Bowel Dis.* **19**, 66–72 (2013).
61. Hanauer, S. Inflammatory bowel disease epidemiology, pathogenesis, and therapeutic opportunities. *Inflamm. Bowel Dis.* **12**, S3–9 (2006).
62. Podolsky, D. Inflammatory Bowel Disease. *N. Engl. J. Med.* **347**, 417–429 (2002).
63. Stetler-Stevenson, W. Type IV collagenase in tumour invasion and metastasis. *Cancer Metastasis Rev.* **9**, 289–303 (1990).
64. Galicia, G. & Ceuppens, J. Haptoglobin function and regulation in autoimmune diseases, acute phase proteins - Regulation and functions of acute phase proteins, (ed. Veas, F.) 229–246 (IntechOpen, 2011). <https://doi.org/10.5772/22483>.
65. Wypasek, E. et al. Fibrinogen beta-chain -C148T polymorphism is associated with increased fibrinogen, C-reactive protein, and interleukin-6 in patients undergoing coronary artery bypass grafting. *Inflammation* **35**, 429–435 (2012).
66. Bailey, C. et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. *J. Clin. Pathol.* **47**, 113–116 (1994).
67. Aamann, L., Vestergaard, E. M. & Gronbaek, H. Trefoil factors in inflammatory bowel disease. *World J. Gastroenterol.* **20**, 3223–3230 (2014).
68. Podolsky, D. K. et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. *J. Biol. Chem.* **268**, 6694–6702 (1993).
69. Kindon, H., Pothoulakis, C., Thim, L., Lynch-Devaney, K. & Podolsky, D. K. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. *Gastroenterology* **109**, 516–523 (1995).
70. Pelaseyed, T. et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. *Immunol. Rev.* **260**, 8–20 (2014).
71. Park, S. W. et al. The protein disulfide isomerase AGR2 is essential for production of intestinal mucus. *Proc. Natl Acad. Sci. USA* **106**, 6950–6955 (2009).
72. Axelrad, J. et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. *Clin. Gastroenterol. Hepatol.* **14**, 58–64 (2016).
73. Pedersen, N. et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. *Am. J. Gastroenterol.* **105**, 1480–1487 (2010).
74. Borregaard, N. & Herlin, T. Energy metabolism of human neutrophils during phagocytosis. *J. Clin. Invest.* **70**, 550–557 (1982).
75. Kominsky, D. J., Campbell, E. L. & Colgan, S. P. Metabolic shifts in immunity and inflammation. *J. Immunol.* **184**, 4062–4068 (2010).
76. Chen, C. et al. Metabolomics reveals that hepatic stearyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. *Cell Metab.* **7**, 135–147 (2008).
77. Toedter, G. et al. Genes associated with intestinal permeability in ulcerative colitis: changes in expression following infliximab therapy. *Inflamm. Bowel Dis.* **18**, 1399–1410 (2012).
78. Jia, H. et al. Multi-faceted integrated omics analysis revealed parsley (*Petroselinum crispum*) as a novel dietary intervention in dextran sodium sulphate induced colitic mice. *J. Funct. Foods* **11**, 438–448 (2014).
79. Jia, H. et al. Coffee intake mitigated inflammation and obesity-induced insulin resistance in skeletal muscle of high-fat diet-induced obese mice. *Genes Nutr.* **9**, 389 (2014).
80. Murakami, S. et al. The consumption of bicarbonate-rich mineral water improves glycemic control. *Evid.-Based Complementary Alternative Med.* **2015**, 824395 (2015).

ACKNOWLEDGEMENTS

This work was supported by a Grant-in-Aid (18K11095) from the Japan Society for the Promotion of Science (JSPS).

AUTHOR CONTRIBUTIONS

H.J. and W.A. designed the research; H.J. and W.A. conducted the animal experiments; W.L. analyzed the proteome data; W.A., S.F., and M.T. analyzed the metabolome data; L.O. and M.H. performed the statistical analysis; W.A. and H.J. wrote the paper. H.K. revised the paper and had primary responsibility for the final content. All authors read and approved the final manuscript. W.A. and H.J. contributed equally to this work.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at <https://doi.org/10.1038/s41538-020-0065-5>.

Correspondence and requests for materials should be addressed to H.J. or H.K.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020